Purchase of pharmaceuticals which treat the underlying cause of cystic fibrosis (CFTR modulators)

Information

15 - Bekendtgørelse med henblik på frivillig forudgående gennemsigtighed
Vejledende kundgøring
04-10-2018 09:18 (GMT+02:00)

Indkøber

Amgros I/S Amgros I/S
Jon Bjergfelt Jon Bjergfelt
Dampfærgevej 22
2100 København Ø
Danmark

Tildelingsinformationer

Cystic fibrosis is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It is caused by the presence of mutations in both copies of the gene for the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein. Today, patients with cystic fibrosis are mainly treated with pharmaceuticals which reduce the symptoms of cystic fibrosis without treating their underlying cause. Amgros wishes to enter into a contract ensuring that public hospitals in Denmark, Greenland and the Faroe Islands will be able to offer all their cystic fibrosis patients treatment with pharmaceuticals, which treat the underlying cause of cystic fibrosis (CFTR modulators).

Mercell A/S

En del af Mercell, en af Europas ledende aktører inden for formidling af information mellem indkøber og leverandør på det professionelle marked. CVR nr. 25698851

Kontakt

Klik her for at gå til support

+45 63 13 37 00
Mercell A/S | B!NGS
Vesterbrogade 149
, 1620 København V, Danmark